Income Statement (Annual)

BSFT / BroadSoft, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Adminstrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016
Net Income Loss Attributable To Noncontrolling Interest -4 4 - - - - - -
Net Income Loss -7,849 7,992 32,297 12,076 -8,874 1,012 179 816
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs Table - - - - - - - -
  Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs By Report Line Axis - - - - - - - -
    Employee Service Share Based Compensation Allocation Of Recognized Period Costs Report Line Domain - - - - - - - -
      Cost Of Sales Member - - - - - - - -
      Selling And Marketing Expense Member - - - - - - - -
      Research And Development Expense Member - - - - - - - -
      General And Administrative Expense Member - - - - - - - -
  Employee Service Share Based Compensation Allocation Of Recognized Period Costs Line Items - - - - - - - -
    Sales Revenue Net
      Technology Services Revenue - 8,578 18,313 16,843 14,728 21,054 46,199 65,034
      License And Maintenance Revenue - 33,743 42,462 58,249 69,357 92,492 112,836 146,615
      Licenses Revenue 37,942 53,302 77,289 89,750 94,408 103,311 119,808 129,313
      Maintenance Revenue 30,945 42,321 60,775 - - - - -
      Sales Revenue Net 68,887 95,623 138,064 164,842 178,493 216,857 278,843 340,962
    Cost Of Goods And Services Sold
      Technology Services Costs - 7,010 8,478 9,012 10,771 14,814 28,925 36,875
      Cost Of Services Licenses And Maintenance Agreements - 7,691 10,419 14,831 21,368 33,232 38,602 46,717
      License Costs 4,432 5,341 5,475 8,643 9,241 9,667 10,231 7,585
      Cost Of Services Maintenance Costs 12,142 14,369 18,204 - - - - -
      Amortization Of Intangible Assets 800 800 1,295 2,700 3,900 5,400 5,800 6,600
      Cost Of Goods And Services Sold 17,374 20,042 24,974 32,486 41,380 57,713 77,758 91,177
    Gross Profit 51,513 75,581 113,090 132,356 137,113 159,144 201,085 249,785
    Operating Expenses
      Selling And Marketing Expense 28,534 31,818 38,376 47,911 62,174 69,681 83,806 107,142
      Research And Development Expense 16,625 19,616 27,744 36,178 49,696 49,515 60,749 77,202
      General And Administrative Expense 11,405 14,103 19,534 22,863 32,580 32,729 41,287 49,934
      Operating Expenses 56,564 65,537 85,654 106,952 144,450 151,925 185,842 234,278
    Operating Income Loss -5,051 10,044 27,436 25,404 -7,337 7,219 15,243 15,507
    Nonoperating Income Expense
      Other Nonoperating Income Expense -110 -174 - - - - - -
      Interest Income Expense Net - - - -6,470 -6,946 -7,177 -9,386 -
      Other Operating Income Expense Net - - - -10 148 -1,300 -5,714 -155
      Interest Income Other - - - - - 529 1,270 2,680
      Investment Income Interest 39 52 278 455 454 - - -
      Interest Expense 1,398 757 3,592 6,925 7,400 7,706 10,656 15,756
      Nonoperating Income Expense -1,469 -879 -3,314 -6,470 -6,946 -8,477 -15,100 -13,231
    Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments -6,520 9,165 24,122 18,934 -14,283 -1,258 143 2,276
    Income Tax Expense Benefit 1,333 1,169 -8,175 6,858 -5,409 -2,270 -36 1,460
    Profit Loss -7,853 7,996 32,297 12,076 -8,874 1,012 179 -
    Earnings Per Share
      Earnings Per Share Basic -0 0 0 0 -0 0 0 0
      Earnings Per Share Diluted -0 0 0 0 -0 0 0 0
    Weighted Average Number Of Shares Outstanding
      Weighted Average Number Of Shares Outstanding Basic 6,285 16,263 26,603 27,581 28,116 28,654 29,113 29,670
      Weighted Average Number Of Diluted Shares Outstanding 6,285 24,721 27,987 28,353 28,116 29,917 29,818 30,898
    Share Based Compensation
      Allocated Share Based Compensation Expense 3,629 3,008 7,201 15,022 41,684 29,628 40,444 51,507
      Share Based Compensation 3,629 3,008 7,201 15,022 41,684 29,628 40,444 51,507

Peers - Prepackaged Software (7372)

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 11133B409